|
|
Vaccine Comparison
|
HIV DNA and adenoviral vector Ad5 expressing SIV gag protein |
HIV-2 DNA vaccine |
| Vaccine Information |
Vaccine Information |
- Vaccine Name: HIV DNA and adenoviral vector Ad5 expressing SIV gag protein
- Vaccine Ontology ID: VO_0000786
- Type: DNA vaccine
- Status: Research
- Antigen: SIVmac239 gag protein (Shiver et al., 2002)
- Gag protein from SIV-mnd 2
gene engineering:
- Type: Recombinant vector construction
- Detailed Gene Information: Click Here.
- Gag protein from SIV-mnd 2
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Vector: V1R plasmid and adenoviral vector (Ad5)
- Preparation: The V1R DNA vector expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells (Shiver et al., 2002). The plasmid DNA vector was formulated in a solution containing a nonionic blocked copolymer adjuvant (CRL1005) (Shiver et al., 2002).
The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).
- Immunization Route: Intramuscular injection (i.m.)
- Virulence: No virulence has been reported associated with this vaccine (Shiver et al., 2002).
- Description: Immunization and viral challenge studies were conducted in rhesus macaques (Macaca mulatta). Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The plasmid DNA vector was formulated in either PBS solution, a solution containing adjuvant, or a solution containing MPL/alum. All immunized animals were genotyped for the MHC class I Mamu-A*01 allele, allowing analysis of the responses of T cells (CD8+) to the test vaccines (Shiver et al., 2002).
|
- Vaccine Name: HIV-2 DNA vaccine
- Vaccine Ontology ID: VO_0004259
- Type: DNA vaccine
- Status: Research
- Antigen: The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004).
- gag
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- nef
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- tat
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- env
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Adjuvant:
- Adjuvant:
- Vector: pND-14 (Locher et al., 2004)
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
References |
Shiver et al., 2002: Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17; 415(6869); 331-5. [PubMed: 11797011].
|
Locher et al., 2004: Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004; 22(17-18); 2261-2272. [PubMed: 15149785].
|
|
